Supraventricular tachycardia has a meaningful genetic component, though genes are far from the whole story. A large twin study in Denmark estimated that about 35% of SVT risk can be attributed to genetics, with the remaining 65% driven by non-shared environmental factors. That split varies depending on the specific type of SVT you’re talking about, because SVT is really an umbrella term covering several distinct rhythm problems, each with its own genetic profile.
What the Twin Evidence Actually Shows
The strongest evidence for a heritable component to SVT comes from a nationwide study of Danish twins. When one identical twin was diagnosed with SVT, the other twin’s risk was substantially higher than it was for fraternal twins. Identical co-twins had roughly 3.6 times the risk of fraternal co-twins, and the rate at which both identical twins ended up with the diagnosis was about 16%, compared to 5% for fraternal pairs. Statistical modeling attributed around 35% of SVT susceptibility to genetic factors and 65% to unique environmental influences, meaning things that differ even between twins raised together.1European Heart Journal. The heritability of supraventricular tachycardia – a nationwide study in Danish twins
That 35% figure is useful as a population-level estimate, but it doesn’t tell you which genes matter or how much they matter for each SVT subtype. The reality is that different forms of SVT sit at very different points on the genetic spectrum, from rare single-gene disorders that run clearly through families to common variants that each nudge risk by a small amount.
SVT Is Not One Condition
Understanding the genetics requires separating SVT into its major subtypes, because the genetic evidence differs dramatically for each. The most common forms are atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular reentrant tachycardia involving an accessory pathway (AVRT, which includes Wolff-Parkinson-White syndrome), and atrial tachycardia. There are also rarer conditions like inappropriate sinus tachycardia, which has its own emerging genetic story. Each of these involves a different electrical problem in the heart, and the genes that influence them don’t overlap as much as you might expect.
Wolff-Parkinson-White Syndrome and Single-Gene Mutations
Wolff-Parkinson-White syndrome is the SVT subtype with the longest and clearest genetic pedigree. In WPW, an extra electrical connection between the upper and lower chambers of the heart creates a shortcut that can trigger rapid heartbeats. Familial WPW, where the condition runs through multiple generations in a family, has been linked to mutations in the PRKAG2 gene, which encodes part of an energy-sensing enzyme in heart cells.2PubMed. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome These mutations cause both the electrical abnormality and unusual thickening of the heart muscle.
Animal studies have confirmed the mechanism. Mice engineered to carry the same PRKAG2 mutation develop the hallmark electrical shortcut seen in WPW patients and can be driven into reentrant tachycardia in the lab, demonstrating that the gene defect alone is sufficient to produce the condition.3PubMed Central. Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome The mutant enzyme’s activity was dramatically reduced compared to normal mice, which fits the idea that disrupted energy metabolism in the developing heart creates the abnormal pathway.
Familial WPW linked to PRKAG2 is rare, but it carries serious risks. One Chinese family with this mutation had an unusually high rate of sudden cardiac death from atrial fibrillation conducted rapidly over the accessory pathway.4PubMed. High risk of sudden death associated with a PRKAG2-related familial Wolff-Parkinson-White syndrome This is a case where knowing about the genetic cause genuinely changes clinical management, because family members who carry the mutation need closer surveillance even if they haven’t had symptoms yet.
AVNRT Runs in Families More Than People Realize
AVNRT is the most common SVT subtype in adults. It happens when electrical signals loop around the area near the AV node, producing episodes of fast heart rate that often start and stop abruptly. For a long time it was considered sporadic, but evidence now suggests a familial component that’s stronger than previously thought.
A study of over 1,500 patients who underwent ablation for AVNRT found that 20 had at least one first-degree relative also diagnosed with the condition. That translated to a familial prevalence of about 127 per 10,000. More strikingly, first-degree relatives of AVNRT patients had at least 3.6 times the risk of developing AVNRT compared to the general population.5PubMed. Familial Occurrence of Atrioventricular Nodal Reentrant Tachycardia The researchers concluded that autosomal dominant inheritance with incomplete penetrance was the most likely explanation, meaning you could carry the genetic predisposition and never develop symptoms. Case reports have documented AVNRT occurring in parent-child pairs, both of whom were successfully treated with catheter ablation.6PubMed Central. Familial occurrence of atrioventricular nodal reentrant tachycardia in a mother and her son
Genome-wide association studies have begun to identify the specific genetic variants involved. A large meta-analysis identified variants near the genes NKX2-5, TTN, and MYH6 that associate with AVNRT risk.7PubMed. Genetic Variants Close to TTN, NKX2-5, and MYH6 Associate With AVNRT NKX2-5 is a transcription factor critical for heart development, and reduced predicted expression of NKX2-5 in heart tissue was associated with higher AVNRT risk.8PubMed Central. Meta-Analysis of Genome-Wide Association Studies Reveals Genetic Mechanisms of Supraventricular Arrhythmias These are common genetic variants, each contributing a small amount of risk, which is a very different genetic architecture from the rare PRKAG2 mutations that cause familial WPW.
Accessory Pathway SVT and GWAS Findings
For SVT caused by accessory pathways more broadly (the category that includes WPW and other AVRT forms), genome-wide association studies have identified a different set of risk genes. A study found significant associations with variants in CCDC141 and SCN10A. The CCDC141 variants each raised the odds of having an accessory pathway by roughly 37% to 55%, while the SCN10A variant increased risk by about 22%.9JAMA Cardiology. Genome-Wide Association Study of Accessory Atrioventricular Pathways All three variants were linked to accessory pathway SVT but not to AVNRT, reinforcing the idea that different SVT subtypes have genuinely distinct genetic underpinnings. The SCN10A variant was also associated with atrial fibrillation, suggesting overlapping genetic architecture between different arrhythmia types.
The broader picture emerging from genetic research is that SVT sits in between the extremes. It’s not a purely monogenic condition like some inherited rhythm disorders, and it’s not purely environmental either. Current evidence supports a model where common genetic variants each contribute a small amount of susceptibility, layered on top of occasional rare variants in biologically relevant pathways.10PubMed Central. Genetics of supraventricular tachycardia: current evidence with a focus on translational relevance and personalized medicine
Inappropriate Sinus Tachycardia Has Its Own Genetic Thread
Inappropriate sinus tachycardia is a less common form of SVT where the heart’s natural pacemaker fires too fast at rest or with minimal exertion, without an obvious cause like fever or dehydration. It has historically been poorly understood and sometimes dismissed as anxiety-related. But genetic studies in affected families have now linked it to mutations in HCN4, the gene encoding a channel protein that helps set the heart’s resting pace.
In a Spanish family with IST, researchers identified a mutation (p.V240M) in HCN4 that produced an abnormally large pacemaker current, essentially making the heart’s internal metronome run too fast. All family members carrying the mutation had IST, and the adults also developed heart muscle thickening over time.11PubMed Central. A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family A second family, reported separately, carried a different HCN4 mutation (p.Asn299Ser) found in an affected mother and child but absent in unaffected siblings. Laboratory testing confirmed that this variant also increased the channel’s activity.12Europace. A novel gain-of-function HCN4 variant responsible for familial inappropriate sinus tachycardia
These findings matter practically because they support the use of ivabradine, a drug that specifically blocks HCN4 channels, in genetically based IST. A recent study confirmed that understanding the mechanism behind the mutation helps explain why ivabradine works for these patients.13PubMed. HCN4 Mutation Causing Familial Inappropriate Sinus Tachycardia Leads to a Conformational Change Mimicking cAMP Binding and Induces Constitutive Channel Activity Only a handful of HCN4 mutations linked to IST have been identified so far, so this remains a rare genetic cause of an already uncommon condition.
When SVT Comes Packaged With a Congenital Heart Defect
Some children are born with SVT as part of a structural heart problem, and in those cases the genetic contribution often comes through the genes responsible for heart development rather than specific arrhythmia genes. Ebstein anomaly, a congenital malformation of the tricuspid valve, is a well-known example. In one study, about 27% of Ebstein anomaly patients had WPW and a broader group had SVT as part of their clinical picture.14PubMed Central. Identification of clinically relevant phenotypes in patients with Ebstein anomaly Case reports document SVT being diagnosed in children with Ebstein anomaly as young as five years old.15PubMed Central. Successful ablation of concealed accessory pathway mediated supraventricular tachycardia in a 5-year-old child with Ebstein anomaly
Inherited metabolic conditions can also produce SVT. Danon disease, a rare genetic disorder affecting cellular recycling machinery, frequently causes WPW-like patterns alongside thickened heart muscle. A study of pediatric Danon patients found that all had both heart muscle thickening and WPW features on their ECGs, and several developed SVT or ventricular tachycardia.16PubMed. Clinical features of pediatric Danon disease and the importance of early diagnosis Similar WPW-like electrical patterns have been described in other inherited conditions involving abnormal storage of glycogen or other molecules in the heart.17EP Europace. Cardiac arrhythmias in patients with Danon disease In these scenarios, the SVT isn’t a standalone genetic condition; it’s a downstream consequence of a broader inherited metabolic problem affecting how the heart develops and functions.
How Age and Sex Shift the Picture in Children
The mix of SVT subtypes isn’t static across childhood, and these age-related shifts offer indirect clues about the underlying biology. A study of over 3,500 pediatric patients found that accessory pathway-mediated SVT was most common in the youngest children and decreased in proportion with age, while AVNRT became progressively more common as children got older.18Congenital Heart Disease. Is the mechanism of supraventricular tachycardia in pediatrics influenced by age, gender or ethnicity? Among adolescents aged 12 to 21, girls were more likely than boys to have AVNRT rather than accessory pathway SVT, a sex difference that wasn’t present in younger children.
These patterns likely reflect how the heart’s conduction system matures. Accessory pathways are thought to be remnants of fetal connections that normally disappear during development. When they persist, they can conduct abnormal circuits. The fact that accessory pathway SVT is most common in very young children and sometimes resolves with age suggests a developmental window influenced by the genetic programs controlling how the conduction system forms.19PubMed Central. Development of the Cardiac Conduction System AVNRT, by contrast, tends to emerge later, perhaps as the AV node takes on its mature electrical properties.
What Genetic Testing Can and Cannot Do Right Now
If you or your child has SVT, you might wonder whether genetic testing makes sense. The honest answer is that it depends heavily on the clinical scenario. For most people with typical AVNRT or a single isolated accessory pathway, genetic testing isn’t part of routine care. The condition is treated successfully with ablation or medication, and knowing the genetic variants involved wouldn’t change the management plan.
The situation is different when SVT occurs alongside heart muscle thickening, when multiple family members are affected, or when the condition appears in infancy. A study of neonatal arrhythmias found that genetic testing identified a probable cause in about 22% of newborns with fast heart rhythms, with SVT being the most common type of tachyarrhythmia.20PubMed Central. Clinical and genetic spectrum of neonatal arrhythmia in a NICU In these young patients, a genetic diagnosis can identify conditions like PRKAG2 cardiomyopathy or Danon disease that require specialized monitoring and family screening.
For familial WPW specifically, identifying a PRKAG2 mutation in one family member has clear implications: other relatives can be tested, and carriers can be monitored for the associated heart muscle changes and sudden death risk that go beyond what you’d expect from ordinary WPW.21PubMed. High risk of sudden death associated with a PRKAG2-related familial Wolff-Parkinson-White syndrome For familial IST, identifying an HCN4 mutation supports the use of ivabradine and helps explain the condition to family members who may have been told their fast heart rate was “just anxiety.”
How Genetics Could Shape Future Treatment
Beyond diagnosis, genetic knowledge is starting to influence how SVT might be treated. The pharmacogenomics angle is underappreciated: people’s genetic makeup affects how they metabolize antiarrhythmic drugs and how susceptible they are to side effects. Variants in genes encoding drug-metabolizing enzymes and ion channel targets can influence both how well a medication works and whether it triggers dangerous rhythm disturbances as a side effect.22PubMed. Pharmacogenetics of antiarrhythmic therapy This is relevant to SVT patients who take medications like flecainide or beta-blockers long-term, though pharmacogenomic testing for arrhythmia drugs is still far from routine practice.
Researchers are also exploring how GWAS findings might eventually lead to risk scores that predict who is most likely to develop SVT or, more usefully, who is most likely to have recurrences after treatment. The identification of specific genes involved in accessory pathway formation and AV node function opens the door to understanding why some pathways conduct dangerously fast while others cause only mild symptoms. GWAS analyses have already shown that variants associated with accessory pathway SVT also correlate with shorter PR intervals and increased heart rate in the general population, suggesting a continuum of electrical properties rather than a sharp line between “normal” and “SVT.”23JAMA Cardiology. Genome-Wide Association Study of Accessory Atrioventricular Pathways
The discovery that genes like SCN10A contribute to both accessory pathway SVT and atrial fibrillation also raises the question of shared pathways between arrhythmias that have traditionally been treated as separate conditions. If common genetic architecture links SVT and atrial fibrillation, treatments developed for one might have relevance to the other. That’s speculative for now, but it’s the direction the field is moving. For the average person with SVT, the practical takeaway is simpler: if multiple family members have it, especially with onset at a young age, it’s worth mentioning to your cardiologist, because the pattern itself is informative even without a genetic test.